FDA Panel Rejects New Uses For Cancer Drug
A joint committee of experts voted by a 17-3 margin on Tuesday against Cephalon's request for expanded label-use of the drug, which is currently only approved for pain management of patients with cancer.
The FDA, which usually follows its advisory board opinions, is expected to decide on Cephalon's application in September.
Cephalon said it was disappointed with the advisory committee's recommendation....
To view the full article, register now.